Blockchain Registration Transaction Record
VERAXA Biotech Unveils BiTAC-ADC Platform Data, Targets Solid Tumors
VERAXA Biotech releases new in vitro data for its BiTAC-ADC platform, showing tumor-specific killing of breast cancer cells with reduced toxicity. The company seeks partnerships at BIO 2026.
This news matters because VERAXA's BiTAC-ADC platform could revolutionize cancer treatment by precisely targeting tumors while sparing healthy cells, reducing debilitating side effects. For patients with solid tumors like breast cancer, this technology offers hope for more effective and safer therapies. The company's pursuit of partnerships at BIO 2026 signals potential accelerated development and broader access to these innovative treatments.
| Blockchain | Details |
|---|---|
| Contract Address | 0xeA2912a8DA1CD48401b10cB283585874d98098F4 |
| Transaction ID | 0x47eeeac44e7cbd1d36b73ac415ba10daf01b5965f52c1846596f8552c3687645 |
| Account | 0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20 |
| Chain | polygon-main |
| NewsRamp Digital Fingerprint | plumyZur-b8a10e3841c426cf3fb61ebd057c67d8 |